top of page

Meet GOLD's next catalyst – Reshema Kemps-Polanco

Season 03: episode 07

In this week’s episode, Helena and Isabel share an interview with GOLD’s next Catalyst Reshema Kemps-Polanco, Executive Vice President and US Head, Novartis Oncology.

In this special extended version of the interview exclusive to the podcast, hear Reshema’s story and insights in full, including the life experiences that have led her to where she is today, her ideas for tackling clinical trial recruitment gaps, why equal representation matters and so much more.


If bite-sized insights are more your thing, look out for the Catalyst interview in the next issue of GOLD – published on 25 October – subscribe for free today!


A little more on GOLD’s guest…


Reshema Kemps-Polanco is Executive Vice President and US Head, Novartis Oncology, where she is responsible for all commercial and medical operations in the US. Starting out her career at Novartis, she initially spent 15 years in various positions and ultimately leading multiple marketing teams within oncology and general medicines. She also served as Assistant to the CEO and Head of North America at Novartis and held other commercial roles of increasing responsibility across multiple therapeutic areas. Reshema then spent six years at J&J, latterly as President, Cardiovascular and Metabolism, and President, Janssen Pharmaceuticals, Puerto Rico, before rejoining Novartis in her current role in 2021.


Reshema has been recognised by the Healthcare Businesswomen’s Association as a Rising Star, by The Network Journal as a top 40 Under 40 achiever and most recently by Savoy Magazine as one of the Most Influential Black Executives in Corporate America. She also proudly served her country as a member of the US Army.

Additional resources


If you’re interested in learning more about the topic areas discussed in this episode, check out the following content:

Click here to subscribe to the weekly newsletter for more insights from GOLD.

Read next

Subscribe to GOLD

 

Sign up to receive a weekly roundup of our latest articles, interviews and more 

bottom of page